1. Goldman JM. Chronic myeloid leukemia: a historical perspective. Semin Hematol. 2010;47(4):302–11.
2. Hoglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94(Suppl 2):S241-7.
3. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343–56.
4. Aladag E, Haznedaroglu IC. Current perspectives for the treatment of chronic myeloid leukemia. Turk J Med Sci. 2019;49(1):1–10.
5. Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol. 2019;12(1):39.
6. Druker BJ, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–17.
7. Sasaki K, et al. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica. 2016;101(8):e324-7.
8. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016;91(2):252–65.
9. Gover-Proaktor A, et al. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells. Leuk Lymphoma. 2019;60(1):189–99.
10. Hochhaus A, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303–9.
11. Baccarani M, Rosti G, Soverini S. Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. Leukemia. 2019;33(10):2358–64.
12. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8(11):1018–29.
13. Al-Dewik NI, et al. Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in the State of Qatar. Biomark Cancer. 2015;7:63–7.
14. Kalle AM, Sachchidanand S, Pallu R. Bcr–Abl-independent mechanism of resistance to imatinib in K562 cells: Induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs). Leuk Res. 2010;34(9):1132–8.
15. Nambu T, et al. Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells. Cancer Sci. 2010;101(1):137–42.
16. Patel AB, O'Hare T, Deininger MW. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors. Hematol Oncol Clin North Am. 2017;31(4):589–612.
17. Machova Polakova K, Koblihova J, Stopka T. Role of epigenetics in chronic myeloid leukemia. Curr Hematol Malig Rep. 2013;8(1):28–36.
18. Heller G, et al. Next-generation sequencing identifies major DNA methylation changes during progression of Ph + chronic myeloid leukemia. Leukemia. 2016;30(9):1861–8.
19. Toyota M, et al. Methylation profiling in acute myeloid leukemia. Blood. 2001;97(9):2823–9.
20. Jelinek J, et al. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One. 2011;6(7):e22110.
21. Wang X, et al. [Methylation status of JunB and CDH13 gene promoter in CD34(+)CD38(-) chronic myelogenous leukemia cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009;17(6):1405–8.
22. Wang Y-l, et al. Methylation status of DDIT3 gene in chronic myeloid leukemia. J Exp Clin Cancer Res. 2010;29:54.
23. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol. 2006;7(11):833–46.
24. Jiang G, Hertog J, Hunter T. Receptor-like protein tyrosine phosphatase alpha homodimerizes on the cell surface. Mol Cell Biol. 2000;20(16):5917–29.
25. Du Y, Grandis JR. Receptor-type protein tyrosine phosphatases in cancer. Chin J Cancer. 2015;34(2):61–9.
26. Della Peruta M, et al. Protein tyrosine phosphatase receptor type is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia. Cancer Res. 2010;70(21):8896–906.
27. Vezzalini M, et al. A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type gamma in chronic myeloid leukemia patients. J Hematol Oncol. 2017;10(1):129.
28. Al-Dewik NI, et al. Novel Molecular Findings in Protein Tyrosine Phosphatase Receptor Gamma (PTPRG) Among Chronic Myelocytic Leukemia (CML) Patients Studied By Next Generation Sequencing (NGS): A Pilot Study in Patients from the State of Qatar and Italy. Blood. 2016;128(22):5427–7.
29. Al-Dewik NI, et al. Molecular Monitoring of patients with Chronic Myeloid Leukemia (CML) in the state of Qatar: Optimization of Techniques and Response to Imatinib. QScience Connect. 2014;2014(1):24.
30. Baccarani M, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84.
31. Steegmann JL, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648–71.
32. Khokhar SK, et al. Evaluation of Maxwell(R) 16 for automated DNA extraction from whole blood and formalin-fixed paraffin embedded (FFPE) tissue. Clin Chem Lab Med. 2011;50(2):267–72.
33. UCSC. Human hg38 chr3:61561571–62297609 UCSC Genome Browser v390. 2013; Available from: https://genome.ucsc.edu/cgi-bin/hgTracks?db=hg38&lastVirtModeType=default&lastVirtModeExtraState=&virtModeType=default&virtMode=0&nonVirtPosition=&position=chr3%3A61561571%2D62297609&hgsid=780556759_Shpm2jlMxywEjyXrNNwjB1gFkQYn.
34. 2019
BiSearch. Primer Design and Search Tool. 2019; Available from: http://bisearch.enzim.hu.
35. Lewin J, et al. Quantitative DNA methylation analysis based on four-dye trace data from direct sequencing of PCR amplificates. Bioinformatics. 2004;20(17):3005–12.
36. Jiang M, et al. Rapid quantification of DNA methylation by measuring relative peak heights in direct bisulfite-PCR sequencing traces. Lab Invest. 2010;90(2):282–90.
37. Mallona I, Díez-Villanueva A, Peinado MA. Methylation plotter: a web tool for dynamic visualization of DNA methylation data. Source Code Biol Med. 2014;9(1):1–5.
38. Mallona I, Diez-Villanueva A, Peinado MA. Methylation plotter: a web tool for dynamic visualization of DNA methylation data. Source Code Biol Med. 2014;9:11.
39. Al-Dewik NI, et al. Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar? Clinical Medicine Insights Oncology. 2016;10:95–104.
40. Piras G, et al. Ptprg and BCR/ABL1 Expression In CML Patients At Diagnosis and Upon TKI Treatment: Preliminary Results. Blood. 2013;122(21):5163–3.
41. Al-Dewik NI, et al. Studying the impact of presence of point mutation, insertion mutation and additional chromosomal abnormalities in chronic myeloid leukemia patients treated with imatinib mesylate in the State of Qatar. QScience Connect. 2014;2014(1):13.
42. Al-Dewik NI, et al. Targeted Exome Sequencing Identifies Novel Mutations in Familial Myeloproliferative Neoplasms Patients in the State of Qatar. Blood. 2014;124(21):5570–0.
43. Behzad MM, et al. Aberrant DNA Methylation in Chronic Myeloid Leukemia: Cell Fate Control, Prognosis, and Therapeutic Response. Biochem Genet. 2018;56(3):149–75.
44. Jelinek J, et al. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One. 2011;6(7):e22110.
45. Byun H-M. DNA Methylation Analysis of 807 Genes in Chronic Myeloid Leukemia and Acute Promyelocytic Leukemia. 2007.
46. Ren. Identification of DNA methylation biomarkers in imatinib-resistant chronic myeloid leukemia cells. 2012.
47. Zhang TJ, et al. SOX30 methylation correlates with disease progression in patients with chronic myeloid leukemia. Onco Targets Ther. 2019;12:4789–94.
48. Xiao J, et al. PTPRG inhibition by DNA methylation and cooperation with RAS gene activation in childhood acute lymphoblastic leukemia. Int J Cancer. 2014;135(5):1101–9.
49. Wang JF, Dai DQ. Metastatic suppressor genes inactivated by aberrant methylation in gastric cancer. World J Gastroenterol. 2007;13(43):5692–8.
50. Cheung AK, et al. Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. Cancer Res. 2008;68(19):8137–45.
51. van Roon EH, et al. Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer. Eur J Hum Genet. 2011;19(3):307–12.